Page results
-
People with the acquired communication disorder aphasia – which involves problems with the understanding or production of speech –have benefitted greatly from a two-year programme of therapy at the National Hospital for Neurology and Neurosurgery at UCLH.
-
UCLH Pain Management Centre is a nationally recognized centre of excellence for people with longstanding pain.
-
The Royal National ENT Voice Centre is a national and international multidisciplinary centre for voice disorders. The voice clinic at the RNENT is one of the oldest in the UK.
-
Read more about the NHS Staff Survey 2024 - we’re the top acute trust to work at for third year running!
-
RNOH are pleased to launch a series of regular Health and Wellbeing Information and Support Sessions to support patients following a cancer diagnosis and also during/after treatment. These…
-
The Adult Acute speech and language therapist (SLTs) work across a range of acute hospital specialities.
-
Here is an invitation to the Medtronic diabetes patient education web events.
-
In the UK in 2020, 23 million Novo Nordisk FlexPen and FlexTouch pre-filled devices were incinerated or sent to landfill as there was no viable recycling alternative.
-
The UCLH@Home service is helping patients like 55-year-old Sherena Kranat to continue their recovery in their own home under the care of their hospital team.
File results
-
FOI/2023/0275 - Trust statistics on spiking
-
FOI/2023/0262 - Clinical trial participation
-
FOI/2023/0332 - Eating disorder services and Advance Decisions/ Directives to refuse medical treatment (ADRTs)
-
FOI/2023/0260 - Treatment for rare diseases: Fabry, Gaucher and Pompe disease and Hunter Syndrome
-
FOI/2023/0249 - Treatments for clotting disorders - Haemophilia B, Von Willebrand Disease
-
FOI/2023/0242 - Treatment of Haemophilia A
-
FOI/2023/0224 - Patients prescribed medical equipment for use in the home
-
FOI/2023/0222 - Contact details for senior screening and immunisations staff
-
FOI/2023/0220 - Internally produced patient information leaflets
-
FOI/2023/0225 - Usage of Dabrafenib + Trametinib in cancer treatment